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ABSTRACT
Background: Smoking is one of the biggest avoidable
causes of morbidity and mortality in the United Kingdom.
This paper quantifies the current health and economic
burden of smoking in the UK. It provides comparisons
with previous studies of the burden of smoking in the UK
and with the costs for other chronic disease risk factors.
Methods: A systematic literature review to identify
previous estimates of National Health Service costs
attributable to smoking was undertaken. Information from
the World Health Organization’s Global Burden of Disease
Project and routinely collected mortality data were used to
calculate mortality due to smoking in the UK. Population-
attributable fractions for smoking-related diseases from the
Global Burden of Disease Project were applied to NHS cost
data to estimate direct financial costs.
Results: Previous studies estimated that smoking costs
the NHS about £1.4 billion to £1.7 billion in 1991 and has
been responsible for about 100 000 deaths per annum
over the past 10 years. This paper estimates that the
number of deaths attributable to smoking in 2005 was
109 164 (19% of all deaths, 27% deaths in men and 11%
of deaths in women). Smoking was directly responsible
for 12% of disability adjusted life years lost in 2002
(15.4% in men; 8.5% in women) and the direct cost to the
NHS was £5.2 billion in 2005–6.
Conclusion: Smoking is still a considerable public health
burden in the UK. Accurately establishing the burden in
terms of death, disability and financial costs is important
for informing national public health policy.
Smoking is a major preventable cause of morbidity
and mortality in the United Kingdom.1 It is an
important cause of cardiovascular disease, chronic
obstructive pulmonary disease (COPD), lung can-
cer and a range of other cancers, peptic ulcer and
various other medical conditions.1 In 2005, self-
reported cigarette smoking among British adults
was 25% among men and 23% among women.2
Despite recent reductions in the prevalence of
smoking, it is still a serious public health problem
in the UK.3
Because smoking imposes a huge burden on
population health and NHS resources, quantifying
the burden is important. Understanding the con-
tribution of smoking to the overall burden of ill
health and to National Health Service costs,
compared with that of other risk factors for
chronic disease, helps inform the prioritisation of
limited NHS resources. In this way policymakers
can understand the relative costs of different risk
factors and assess whether efforts to alter popula-
tion levels of risk could reduce overall costs to the
NHS.
There have been various attempts to quantify
the health and economic burden of smoking-
related ill health in the UK. The direct healthcare
costs of smoking were estimated to be between
£1.4 billion and £1.7 billion in 1991.4 5 More recent
estimates of the numbers of deaths attributable to
smoking include 114 000 in 20006 and 106 000 per
annum between 1998 and 2002.7 The complexities
of cost of illness studies mean they are not
conducted regularly.
Providing estimates of the health and economic
burden of smoking that are up to date is necessary
as the prevalence of smoking is decreasing (though
less so in recent years), total healthcare costs are
increasing and new interventions aimed at redu-
cing the prevalence of smoking have recently been
implemented—notably the ban on smoking in
public places—all of which are likely to have had
an effect on the burden of smoking-related ill
health. These changes are subject to time lags in
the changing disease outcomes and in the pre-
valence figures as shown by health surveys. A
method is needed, which is relatively fast and easy,
to estimate the costs of smoking to the NHS.
We have proposed a relatively simple and
efficient method to generate estimates of the
burden of ill health related to disease risk factors
of public health concern and have applied this
method to generate estimates for diet, physical
inactivity and obesity.8–10 The potential for such a
standard method that is simple and reliable is
worthy of attention. The estimates this method
generates give similar results to more complex
methods.10
This paper uses this simple method to estimate
the costs of ill health attributable to smoking in the
UK. The results are compared with previous
estimates—in particular estimates generated by a
systematic review of studies of the economic costs
of smoking-related ill health in the UK.
METHODS
First, a systematic review of previous studies of the
economic costs of smoking-related ill health in the
UK was carried out. This review aimed to include
all studies, published between 1997 and 2007,
which calculated the cost of smoking in the UK or
any country of the UK.
Secondly the burden of ill health due to smoking
in all four countries of the UK was calculated using
routinely collected mortality data and data on
NHS costs, together with population attributable
fractions (PAFs) and other information from the
World Health Organization’s Global Burden of
Disease Project. The PAFs generated by this project
estimate the proportion of disease that can be
attributed to a particular risk factor by sex and
region. This study used the same methods that
have been used to estimate the cost of ill health
attributable to other risk factors for chronic disease
in the UK.8–10
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Systematic review
The systematic search of the literature was conducted using the
search terms ‘‘cost’’ and ‘‘smoking’’ in Medline, CINAHL,
Embase, Cochrane Library, National Health Service Economic
Evaluation Database, EconLit, Science Citation Index, Social
Science Citation Index, Index to Scientific and Technical
Proceedings and the Health Management and Policy Database
from the Healthcare Management Information Consortium. An
initial search strategy was developed and tested on Medline and
the search terms were then used for the other databases.
Studies were included if they related to the cost of smoking to
the NHS in the UK and were published in English between
August 1997 and September 2007. The time limits were applied
to ensure that only recent cost estimates were considered. The
reference lists of all papers were reviewed to identify other
potentially relevant studies. Only studies reporting a new
analysis of the cost to the NHS in the UK were included. Studies
reporting previous analyses or estimates based on no analysis
were excluded.
Burden of disease study
The method for calculating the health burden due to smoking
and the direct cost of smoking to the NHS involved five steps.
They were:
c Step 1: Diseases where smoking is a risk factor (as defined by
WHO) were identified from the World Health Report for
2002.11
c Step 2: Data on years of life lost (YLL), years of healthy life
lost to disability (YLD) and disability adjusted life years
(DALYs) for the year 2002 were taken from WHO’s Global
Burden of Disease Project for WHO Euro-A Region (United
Kingdom and other European countries with very low child
and very low adult mortality).11 12 Data on mortality for the
year 2005 was obtained directly from Office for National
Statistics for England and Wales, and the General Register
Offices for Scotland and Northern Ireland.13–15
c Step 3: In 1996, the National Health Executive published a
study which ascribed 1992–3 NHS costs to different diseases
as defined by the International Classification of Disease
(ICD 9).16 NHS total costs were defined in this document as
the sum of NHS inpatient and outpatient costs, NHS
primary care expenditure, NHS pharmaceutical expenditure
and NHS net community care services expenditure. The
proportion of total NHS expenditure (on NHS inpatient and
outpatient costs, NHS primary care expenditure, etc) by
disease code in 1992–3 was applied to the total cost of the
NHS in 2005–6 for all four countries in the UK to provide an
estimate of the total NHS costs for diseases that were
identified as being related to smoking.17–20 The diseases
related to smoking were considered to be those ascribed
within the Global Burden of Disease Project including
mouth and oral cancer, trachea/bronchus and lung cancer,
chronic obstructive pulmonary disease and cardiovascular
disease.11 12
c Step 4: Estimates of the burden of disease in the PAFs were
calculated by the Global Burden of Disease Project.21 The
PAFs for smoking, by sex and condition and relevant to the
UK, were extracted from the World Health Report 2002.11
The smoking PAFs were calculated using a base theoretical
population in which all individuals had no tobacco use.11 12
c Step 5: The burden (in terms of economic cost, mortality
and morbidity) of smoking was calculated by applying the
PAFs for diseases related to smoking to 2005–6 disease-
specific data. Cost data for each of the four countries in the
UK were derived using the method described in step 3.
Mortality data four each of the four countries in the UK
were taken from routinely collected sources.13–15
RESULTS
Systematic review
The search strategy generated 4338 papers of possible relevance.
After applying the inclusion criteria 4207 were rejected on the
basis of title or abstract and a further 135 were rejected after
reviewing the full paper. The majority of papers were excluded
because they reported on the cost of smoking in countries other
than the UK—mostly the United States. Some studies were
excluded because they only reported the costs of a particular
Table 1 Summary of studies included in review with direct healthcare cost of ill health attributable to
smoking in the United Kingdom
Reference Setting Direct cost (method) Disease included in estimate
Parrott et al, 19984 England, 1991 Method 1: Cancer
£1.5 billion (attributable fractions) Lung, upper respiratory sites,
oesophagus, bladder
kidney, stomach, pancreas, myeloid
leukaemia
Method 2:
£1.4 billion (cost comparison:
smokers versus non-smokers)
Respiratory
Chronic obstructive pulmonary
disease, pneumonia
Circulatory
Ischaemic heart disease,
cerebrovascular disease, aortic
aneurysm, amyocardial degeneration,
atherosclerosis
Digestive
Ulcer of stomach and duodenum
Buck et al, 19975 UK, 1991 Method 1: Not specified
£1.7 billion (attributable fractions)
Method 2:
£1.4 billion (using 1994 General
Household Survey data and cost to
the NHS of treating illnesses
caused by smoking)
NHS, National Health Service.
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intervention, such as smoking cessation or nicotine replacement
patches.
There were two studies that met the inclusion criteria and
reported on the economic cost of smoking to the NHS in the
UK.4 5 Both studies provide estimates for 1991 ranging from
£1.4. billion to £1.7 billion and are summarised in table 1.
Parrott et al4 produced similar cost estimates using two different
approaches; the application of attributable fractions to 1991
cost data for diseases including a number of cancers, respiratory
and circulatory diseases and by comparing the costs of smokers
and non-smokers. Buck et al5 produced a slightly higher estimate
also using a PAF although comparisons between these studies
are difficult because the diseases included in the second study
were not specified.
Burden of disease study
Morbidity and mortality
Table 2 shows the proportion of deaths, YLLs, YLDs and DALYs
in WHO EUR-A region by disease for 2002. It shows that those
diseases associated with smoking were responsible for 74% of all
mortality, 67% of YLLs, 18% of YLDs and 41% of DALYs.
Table 3 shows the total DALYs lost and the PAFs for
smoking-related ill health in WHO EUR-A region for 2002. It
shows that 12.1% (male: 15.4%; female: 8.5%) of all DALYs lost
were directly attributable to smoking. Cardiovascular disease
was the largest contributor to the burden of disease attributable
to smoking, accounting for 3.8% of all DALYs lost followed by
trachea/bronchus/lung cancer (2.7%) and chronic obstructive
pulmonary disease (2.3%).
Using PAFs derived from the WHO’s Global Burden of
Disease Project, we estimated that of the 588 478 deaths in the
UK in 2005, 109 164 deaths (18.6%) were directly attributable
to smoking (27.2% of all male deaths (77 154) and 10.5% of all
female deaths (32 010)). The proportion of deaths attributable
to smoking ranged from 19.7% in Scotland to 12.2% in
Northern Ireland (table 4).
Direct cost to the NHS
Table 5 shows that the direct cost to the NHS for smoking
attributable conditions was estimated to be £5.17 billion (5.5%
of total healthcare costs) in 2005–6. Of the £5.17 billion directly
attributable to smoking, the largest proportion was due to
cardiovascular diseases (£250.8 million). Table 5 also shows the
direct cost to the NHS for smoking attributable conditions by
countries in the UK.
DISCUSSION
We estimate that 109 164 deaths (18.6% of all deaths) in the UK
in 2005 can be attributed to smoking (27.2% of male deaths and
10.5% of female deaths). Our estimate is similar to that
produced by Twigg et al—that on average, each year 106 100
deaths (17.2% of all deaths) were from smoking-attributable
causes across the UK over the period 1998–2002 (23% of male
deaths and 12% of female deaths).7 Other previous estimates of
smoking attributable deaths include 120 000 in 1995 by Callum
et al,22 117 400 in 1997 by the Royal College of Physicians23 and
114 000 in 2000 by Peto et al.6 This suggests that overall
numbers of deaths attributable to smoking in the UK have not
changed much in the past 10 years.
It is difficult to compare estimates of the number of smoking
attributable deaths because of methodological differences, the
changing prevalence of smoking, changes in the resident
population (57 million in 1991 to 61 million in 2006 in the
UK), etc. For example Callum and White24 used age-specific
attributable fractions for London to derive estimates across all
boroughs and parliamentary constituencies—an approach that
underestimates the attributable burden of smoking in areas
where smoking prevalence is higher than in London and
overestimates the effect where smoking rates are lower than
in London. Twigg et al7 used the same published relative risk
factors as Callum and White to calculate smoking attributable
mortality for primary care trusts and strategic health authorities
in England. These authors extended the previous approach by
Table 2 Proportion of deaths (mortality), years of life lost in early deaths (YLLs), years of life lost in disability
(YLDs) and disability adjusted life years (DALYs) due to smoking-related diseases in WHO-EUR-A region, 2002
% of mortality % of YLLs % of YLDs % of DALYs
(n = 3 920 000 ) (n = 23 972 000) (n = 27 762 000) (n = 51 734 000)
Conditions related to smoking
Mouth and oral cancer 0.6 1.0 0.1 0.5
Trachea/bronchus/lung cancer 5.3 6.8 0.2 3.2
Other cancers 21.4 25.1 2.9 13.2
Chronic obstructive pulmonary
disease
3.6 2.6 4.1 3.4
Cardiovascular diseases 41.1 29.5 6.4 17.1
Other medical conditions* 2.5 2.0 4.7 3.5
Total related to smoking 74.4 66.9 18.3 40.8
Communicable diseases, maternal/
perinatal conditions and nutritional
deficiencies
6.2 6.0 4.0 4.9
Digestive diseases{ 4.2 5.2 3.8 4.4
Diabetes mellitus 2.4 1.9 2.4 2.1
Diseases of the genitourinary
system
1.6 1.1 1.0 1.1
Neuropsychiatric disorders 4.7 4.8 45.3 26.5
Musculoskeletal diseases 0.5 0.4 7.6 4.3
Injuries 4.8 11.5 4.7 7.9
Other 1.2 2.3 12.9 7.9
Total 100.0 100.0 100.0 100.0
*Includes peptic ulcer and all respiratory conditions except chronic obstructive pulmonary disease. {Excluding peptic ulcer.
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applying multi-level synthetic estimation techniques to produce
estimates at small area level and combining primary care trusts
estimates to create figures for the four countries within the UK.
The decline in overall prevalence of smoking together with
the increase in smoking among younger age groups increases the
complexity of the issue. In this study we used the WHO’s
(2002) population attributable fractions for smoking-related
conditions and the latest (2005) mortality data for the UK. This
study therefore provides the most up-to-date estimates of the
burden of smoking-related illness.
Our study estimates that smoking cost the NHS over £5
billion in 2005–6. This equates to 5.5% of total NHS
expenditure in 2005–6. The systematic review identified two
studies that estimated the cost of smoking to the NHS. The first
study estimated the cost to be between £1.4 billion and £1.5
billion in 19914 and the second study estimated the cost
between £1.4 billion and £1.7 billion in the same year.5
However, the total NHS healthcare cost has gone up from
£31 billion in 1991–2 to £80 billion in 2005–6,16 17 so although
our estimate is higher than these previous estimates, it does not
differ greatly as a proportion of total healthcare costs (4.9% to
5.5% in 1991 compared to 5.5% in 2005–6). We can assume that
much of the difference in cost was due to the increase in overall
healthcare costs since 1991.
Another potential source of difference between our estimate
of the cost of smoking to the NHS and previous estimates is the
PAFs used. Both the previous studies used smoking attributable
fractions calculated for 1991 taken from Callum (1995),22 while
our study used PAFs for 2002 from WHO’s World Health
Report.11 Our estimate that smoking was responsible for 5.5% of
total healthcare costs is comparable with estimates of the
economic burden in other developed countries. These estimates
range from 11.8% of total healthcare costs (in the United States
in 199325) to 3.3% (in Germany in 200326).
In this paper we have underestimated the burden of smoking-
related ill health for three reasons. First, we have not included
indirect costs in our economic analysis; second, we have not
included the burden due to passive smoking; and, third, we have
not considered all conditions related to smoking. Indirect costs
include those caused by production losses due to smoking-
related premature mortality, morbidity and informal care of
people with smoking-related illnesses, but also other costs such
as sickness absence payments and the costs of smoking-related
fires. For Scotland, Parott et al estimated that the annual cost of
smoking-related productivity losses, absence from work and fire
associated with smoking were, in 2000, £40 million, £450
million and £4 million, respectively.27 Including indirect costs
would increase our estimate of the financial burden considerably.
The British Medical Association estimates that each year in
the UK at least 1000 people die as a result of secondhand
smoke28 and more than 17 000 children under the age of 5 are
admitted to hospital because of the effects of passive smoking.29
Parrott and Godfrey have estimated that each year in the UK
£410 million is spent in treating childhood illnesses related to
Table 3 Total disability adjusted life years (DALYs) lost and population attributable fractions for smoking-related ill, by gender, in WHO EUR-A region,
2002
Smoking-related
conditions
Male Female Total
DALYs lost
(n)
PAF
DALYs
lost (%)
DALYs lost
to smoking
% of
all
male
DALYs
DALYs lost
(n)
PAF
DALYs
lost (%)
DALYs lost
to smoking
% of all
female
DALYs
DALYs lost
(n)
PAF
DALYs
lost (%)
DALYs lost
to smoking
% of all
DALYs
Mouth and oral
cancer
213 052 0.0 0 0.0 50 554 0.0 0 0.0 263 605 0.0 0 0.0
Trachea/bronchus/
lung cancer
1 237 789 90.0 1 114 010 4.1 429 890 69.0 296 624 1.2 1 667 678 85.0 1 410 633 2.7
Other cancers 3 344 506 19.0 635 456 2.3 3 457 554 2.0 69 151 0.3 6 802 060 10.0 704 607 1.4
Chronic obstructive
pulmonary disease
908 350 79.0 717 597 2.6 836 077 57.0 476 564 2.0 1 744 427 68.0 1 194 161 2.3
Cardiovascular
diseases
5 004 686 32.0 1 601 499 5.9 3 833 645 10.0 383 365 1.6 8 838 331 22.0 1 984864 3.8
Other medical
conditions*
978 824 16.0 156 612 0.6 812 751 6.0 48 765 0.2 1 791 575 11.0 205 377 0.4
Total related to
smoking
10 708 383 39.3 4 211 964 15.4 8 607 719 24.0 2 065 853 8.5 19 316 102 33.0 6277 817 12.1
*Includes peptic ulcer disease and all respiratory conditions except COPD. {Excluding peptic ulcer disease.
COPD, chronic obstructive pulmonary disease; PAF, population attributable fractions.
Table 4 Total deaths and deaths attributable to smoking by gender and countries in the UK, in 2005
All ages
England Wales Northern Ireland Scotland UK total
All deaths
Male 227 479 15 146 14 224 26 522 283 371
Female 251 967 16 958 6957 29 225 305 107
Total 479 446 32 104 21 181 55 747 588 478
Deaths attributable to smoking
Male 63 462 4343 1863 7485 77 154
Female 26 001 1808 720 3481 32010
Total 89 463 6152 2583 10 966 109 164
% deaths attributable to smoking 18.7 19.2 12.2 19.7 18.6
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passive smoking.30 If these estimates are correct then including
the effects of passive smoking would substantially increase our
estimates of the health and financial burden due to smoking.
The analysis presented here only considered conditions for
which the WHO Burden of Disease Study has calculated PAFs.
Our report did not include other conditions reported to be
associated with smoking such as infertility, complications
during pregnancy, stillbirths, neonatal deaths, post-menopausal
osteoporosis, eye diseases, etc.31 32 The WHO Global Burden of
Disease data are also limited by the lack of age-specific
information. The application of a single estimate across the
total adult population assumes that disease patterns are
consistent across all age groups.
A further limitation to this and similar studies is the absence
of current NHS cost data by disease category. In this study the
data had to be extrapolated from 1992 data (because there is no
more recent study) and clearly methods of treating diseases
associated with smoking (and the costs associated with those
methods) have changed significantly since then. In 2002, the
Department of Health initiated the National Programme Budget
Project (NPBP), which provides detailed expenditure informa-
tion for primary care service under 23 programmes of care based
on medical conditions such as mental health, cardiovascular
disease and cancer. While these data are only available for
England and only for some specific disease categories they
provide a chance to understand the change in relative proportion
of costs for these diseases between 1992 and 2006–7. In 2005–6
the NPBP reported problems of circulation as costing £6.1
billion, obstructive airway disease £534 million and infectious
diseases at £1.2 billion. For England our method returned
estimates £9.7 billion for cardiovascular disease, £1.7 billion
for COPD and £834 million for infectious disease.
The methods used for this study only provides a picture of
the past burden of smoking because of its retrospective nature,
and does not reflect the success or otherwise of recent
interventions. This is because of the lag time between any
intervention and the subsequent influence on disease outcomes.
As one example, Peto6 found that people who stop smoking
before middle age will avoid 90% of the risk attributable to
tobacco but the effect of cessation would not show itself on
hospital costs until later life when the symptoms of lung cancer
would manifest.
These limitations notwithstanding, comparative information
about the costs of smoking and other risk factors for chronic
disease is important in making resource allocation decisions
regarding smoking cessation and other preventive actions.
Previous work using the methods used here has estimated
2002 costs due to poor diets in the UK to be £6 billion,
overweight and obesity to be £3 billion and physical inactivity
to be £1 billion.8–10 This study enables a comparison to be made
between the direct cost of smoking to the NHS and other
disease risk factors. This comparison should help policymakers
prioritise public health interventions and make effective use of
limited NHS resources.
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What this paper adds
c The cost of smoking-related ill health to the National Health
Service in the UK is £5.2 billion per year, nearly 5.5% of the
total NHS budget.
c The cost of smoking to the NHS, as a proportion of the total
NHS budget, has not changed substantially since the early
1990s.
c The cost of smoking to the NHS is comparable to the cost of
diet-related ill health, estimated to be approximately £6.0
billion per year.
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